QR код

Stereotactic body radiotherapy with CyberKnife® System for low- and intermediate-risk prostate cancer: clinical outcomes and toxicities of CyPro Trial

Simple summaryStereotactic body radiotherapy (SBRT) of 35–36.25 Gy in five fractions with the CyberKnife System yields excellent control with low toxicity in low–intermediate-risk prostate cancer patients. We found no differences in biochemical control and overall survival in relation to dose. There...

Повний опис

Збережено в:
Автори: Valentina Borzillo, Esmeralda Scipilliti, Donato Pezzulla, Marcello Serra, Gianluca Ametrano, Giuseppe Quarto, Sisto Perdonà, Sabrina Rossetti, Sandro Pignata, Anna Crispo, Piergiacomo Di Gennaro, Valentina D’Alesio, Cecilia Arrichiello, Francesca Buonanno, Simona Mercogliano, Antonio Russo, Antonio Tufano, Rossella Di Franco, Paolo Muto
Формат: Artigo
Мова:Inglês
Опубліковано: Frontiers Media S.A. 2023-11-01
Серія:Frontiers in Oncology
Предмети:
clinical outcome
toxicity
low-and intermediate-risk
radiotherapy
prostate cancer
stereotactic body radiation
Онлайн доступ:https://www.frontiersin.org/articles/10.3389/fonc.2023.1270498/full
Теги: Додати тег
Немає тегів, Будьте першим, хто поставить тег для цього запису!

Схожі ресурси